Arbutus Biopharma Corp expected to post a loss of 8 cents a share - Earnings Preview

Arbutus Biopharma

14/03/2025 13:09

Arbutus Biopharma Corp ABUS.OQ ABUS.O is expected to show a fall in quarterly revenue when it reports  results on March 17 (estimated) for the period ending December 31 2024

The Warminster Pennsylvania-based  company is expected to report a 27.1% decrease in revenue to $1.563 million from $2.15 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Arbutus Biopharma Corp is for a loss of 8 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Arbutus Biopharma Corp is $5.00​, above​ its last closing price of $3.32. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.09
-0.09
-0.09
Met
4.9
Jun. 30 2024
-0.09
-0.10
-0.11
Missed
-13.6
Mar. 31 2024
-0.11
-0.11
-0.10
Beat
9.1​
Dec. 31 2023
-0.12
-0.12
-0.12
Met
-1.7
​​Sep. 30 2023
-0.11
-0.11
-0.12
Missed
-5.4
Jun. 30 2023
-0.11
-0.11
-0.10
Beat
10.9​
Mar. 31 2023
-0.14
-0.14
-0.10
Beat
26.5
Dec. 31 2022
-0.13
-0.13
-0.14
Missed
-5.2

This summary was machine generated March 14 at 13:09 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)